Inclusion Criteria:

• Patients must have locally advanced or metastatic solid tumors.
• Patient is male or female greater than or equal to 18 years of age.
• Female patients of childbearing potential has a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication
• Patients will be limited to 2 prior cytoxic therapies for metastatic or recurrent diseases
• Patient is able to swallow capsules and has no surgical or anatomical condition that will prevent the patient from swallowing

Exclusion Criteria:

• Patient has had chemotherapy, radiotherapy or biological therapy with 4 weeks
• Patients must be least 4 weeks post-surgery and do not expect major surgery in the study duration
• Patient is currently participating or has participated in a study with an investigational compound or device within 30 days
• Patient has known active CNS metastases and/or carcinomatous meningitis
• Patient with a primary central nervous system tumor
• Patient has known hypersensitivity to the components of study drug
• Patient has a history or current evidence of heart disease
• Patient has evidence of clinically significant bradycardia (slow heart rate)
• Patient has uncontrolled high blood pressure
• Patient at significant risk for hypokalemia (low potassium levels)
• Patient is a known diabetic patient
• Patient has known psychiatric or substance abuse disorders
• Patient is a user of illicit drugs
• Patient is pregnant or breastfeeding
• Patient is HIV positive
• Patient has known history of Hepatitis B or C or active Hepatitis A
• Patient has symptomatic ascites or pleural effusion
• Patient is receiving treatment with oral corticosteroids
• Patient is using a potent CYPA4 inhibitor or inducer